telehealth glp-1 crackdown news FDA issued 25 warning letters to companies for false and misleading claims about compounded products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of The FDA is cracking down

This suggests that if HS-10535s structure indeed originates from patent WO2025026270A1, its design is likely based on an optimization and modification of Orforgliprons structure

[1] A potential tapering approach, based solely on clinical judgment rather than formal guidelines or comparative studies, might involve reducing the dose by one step every 46 weeks

Take Our Poll: How do you feel about using medications like Ozempic for weight loss

Compounding pharmacies, outsourcing facilities and telehealth prescribers should carefully review their GLP-1 compounding operations, documentation practices and prescriber significant difference determinations in light of this restated guidance